AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
4D Molecular Therapeutics Inc (NASDAQ:FDMT)
9.09 USD
-0.920 9.191%Sponsored Reports
Loading...
| Previous Close (in USD) | 10.01 |
|---|---|
| Change | -0.920 9.191% |
| 52 W H/L (in USD) | 12.340/3.000 |
| EBITDA (in USD) | -151.653M |
| PE Ratio | -- |
| Volume | 216005 |
| Diluted Eps TTM | -2.42 |
| Total Assets (in USD) | 566.711M |
|---|---|
| Total Liabilities (in USD) | 61.047M |
| Revenue TTM (in USD) | 85.209M |
| Cash (in USD) | 60.241M |
| Market Cap (in USD) | 498.263 M |
| Revenue Per Share TTM | 1.471 |
| Gross Profit TTM (in USD) | -107.287M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
5858 Horton Street, EmeryVille, CA, United States, 94608
510 505 2680
Employees: 196
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. John F. Milligan Ph.D. | Exec. Chairman | 1961 |
| 2. | Dr. David H. Kirn M.D. | Co-Founder, CEO & Director | 1962 |
| 3. | Ms. Theresa Janke | Co-Founder & Chief of Staff | 1975 |
| 4. | Mr. August J. Moretti Esq., J.D. | Chief Financial Officer | 1951 |
| 5. | Dr. Fred Kamal Ph.D. | Pres & COO | 1963 |
| 6. | Mike Zanoni | VP of Investor Relations | NA |
| 7. | Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal & HR Officer and Corp. Sec. | 1972 |
| 8. | Dr. Robert S. Fishman | Chief Medical Officer & Therapeutic Area Head of Pulmonology | 1962 |
| 9. | Dr. Raphael Schiffmann M.D. | Sr. VP & Therapeutic Area Head of Cardiology | NA |
| 10. | Dr. Robert Y. Kim M.B.A., M.D. | Sr. VP & Clinical Therapeutic Area Head of Ophthalmology | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.475 1.086% | 44.05 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.004 0.008% | 43.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+10.610 2.402% | 446.03 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+8.070 1.284% | 632.26 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -140.109M | -160.868M | -100.837M | -107.494M | -71.317M |
| Minority Interest | - | - | - | - | - |
| Net Income | -140.109M | -160.868M | -100.837M | -101.076M | -68.297M |
| Selling General Administrative | 49.06M | 46.579M | 36.494M | 32.908M | 28.011M |
| Gross Profit | 77.584M | 0.037M | -76.373M | 3.129M | 18.038M |
| Reconciled Depreciation | 7.625M | 6.705M | 5.624M | 3.88M | 3.02M |
| Ebit | -159.547M | -187.841M | -112.867M | -113.912M | -74.353M |
| Ebitda | -151.922M | -181.136M | -108.663M | -110.032M | -71.333M |
| Depreciation And Amortization | 7.625M | 6.705M | 4.204M | 3.88M | 3.02M |
| Operating Income | -159.547M | -187.841M | -112.867M | -110.032M | -71.333M |
| Other Operating Expenses | 244.756M | 187.878M | 133.59M | 113.161M | 89.371M |
| Interest Expense | - | - | - | 6.418M | 3.036M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 19.475M | 27.05M | 9.169M | 2.573M | 0.137M |
| Net Interest Income | 19.475M | 27.05M | 9.169M | 2.573M | 0.137M |
| Income Tax Expense | - | - | 5.581M | -6.418M | -3.02M |
| Total Revenue | 85.209M | 0.037M | 20.723M | 3.129M | 18.038M |
| Total Operating Expenses | 237.131M | 187.878M | 36.494M | 113.161M | 89.371M |
| Cost Of Revenue | 7.625M | 6.705M | 97.096M | - | - |
| Total Other Income Expense Net | 19.438M | 26.973M | 12.03M | 2.538M | 0.016M |
| Net Income From Continuing Ops | -140.109M | -160.868M | -95.933M | -107.494M | -71.317M |
| Net Income Applicable To Common Shares | - | - | - | -107.494M | -71.317M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 566.711M | 560.384M | 339.891M | 261.846M | 353.487M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 10.479M | 10.055M | 8.356M | 6.957M | 8.456M |
| Total Liab | 61.047M | 49.778M | 32.062M | 30.509M | 560.483M |
| Total Stockholder Equity | 505.664M | 510.606M | 307.829M | -314.49M | -206.996M |
| Other Current Liab | 26.874M | 18.869M | 12.014M | 8.87M | 7.744M |
| Common Stock | 0.006M | 0.005M | 0.004M | 0.003M | 0.003M |
| Capital Stock | 0.006M | 0.005M | 0.004M | 0.003M | 0.003M |
| Retained Earnings | -716.304M | -576.195M | -415.327M | -314.49M | -206.996M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 1.08M | 0.602M |
| Cash | 60.241M | 149.336M | 249.108M | 218.642M | 315.429M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 43.985M | 29.149M | 18.951M | 15.731M | 16.338M |
| Current Deferred Revenue | 0.36M | 0.257M | 0.273M | 0.884M | 2.599M |
| Net Debt | -38.828M | -124.73M | -234.437M | -202.518M | -298.981M |
| Short Term Debt | 5.592M | 5.637M | 3.149M | 2.655M | 1.231M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 21.413M | 24.606M | 14.671M | 16.124M | 16.448M |
| Other Stockholder Equity | 1221.235M | 1086.567M | 723.136M | 1.193M | 0.42M |
| Property Plant Equipment | - | - | - | 22.262M | 28.953M |
| Total Current Assets | 413.134M | 434.932M | 296.588M | 220.511M | 315.429M |
| Long Term Investments | 111.379M | 80.583M | 10.954M | 4.908M | 67.652M |
| Short Term Investments | 342.414M | 275.541M | 39.124M | 161.203M | 94.776M |
| Net Receivables | - | - | - | 0.7M | 0.047M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | -8.503M |
| Accounts Payable | 11.159M | 4.386M | 3.515M | 3.322M | 4.764M |
| Accumulated Other Comprehensive Income | 0.727M | 0.229M | 0.016M | -1.196M | -0.423M |
| Non Currrent Assets Other | 120.567M | 4.261M | 0.684M | 1.08M | -58.547M |
| Non Current Assets Total | 153.577M | 125.452M | 43.303M | 41.335M | 38.058M |
| Capital Lease Obligations | 21.413M | 24.606M | 14.671M | 16.124M | 16.448M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -92.437M | -302.437M | 86.62M | -5.514M | -163.57M |
| Total Cashflows From Investing Activities | -92.973M | -302.437M | 115.717M | -17.05M | -172.68M |
| Total Cash From Financing Activities | 112.96M | 337.25M | 156.832M | 3.085M | 118.089M |
| Net Income | -140.109M | -160.868M | -100.837M | -107.494M | -71.317M |
| Change In Cash | -89.095M | -99.772M | 196.757M | -100.65M | -123.725M |
| Begin Period Cash Flow | 149.336M | 249.108M | 52.351M | 153.001M | 276.726M |
| End Period Cash Flow | 60.241M | 149.336M | 249.108M | 52.351M | 153.001M |
| Total Cash From Operating Activities | -109.082M | -134.585M | -75.792M | -86.685M | -69.134M |
| Depreciation | 7.625M | 6.705M | 5.749M | 3.88M | 3.02M |
| Other Cashflows From Investing Activities | -0.536M | -3.786M | 173.29M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | -4.536M |
| Sale Purchase Of Stock | 7.5M | - | - | -0.468M | 114.729M |
| Other Cashflows From Financing Activities | 112.96M | 5.838M | 8.488M | 0.355M | 3.793M |
| Capital Expenditures | 0.536M | 3.786M | 2.771M | 11.536M | 9.11M |
| Change In Working Capital | 6.172M | 0.537M | 0.63M | -1.336M | -15.534M |
| Other Non Cash Items | -4.786M | -7.075M | -0.999M | 1.144M | 0.898M |
| Free Cash Flow | -109.082M | -138.371M | -78.563M | -98.221M | -78.244M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 1706213 |
| 2. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 1380384 |
| 3. | iShares Russell 2000 ETF | 2 months ago | 1061652 |
| 4. | Janus Henderson Gbl Life Sciences Divers | 8 months ago | 851188 |
| 5. | Janus Henderson Global Life Sciences | 5 months ago | 842520 |
| 6. | Janus Henderson Global Life Sciences D | 4 months ago | 840162 |
| 7. | Janus Henderson Glb Life Scn I2 USD | 3 months ago | 795179 |
| 8. | Federated Hermes MDT SCC Institutional | 5 months ago | 751892 |
| 9. | Federated Hermes MDT Small Cap Core IS | 5 months ago | 751892 |
| 10. | Janus Global Life Science AUSD | 5 months ago | 744402 |
| 11. | Janus Henderson Hrzn Biotec E2 USD | 5 months ago | 648773 |
| 12. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 441987 |
| 13. | Nuveen Quant Small Cap Equity R6 | 3 months ago | 396500 |
| 14. | Fidelity Small Cap Index | 4 months ago | 389586 |
| 15. | iShares Russell 2000 Value ETF | 2 months ago | 378230 |
| 16. | iShares Biotechnology ETF | 2 months ago | 339448 |
| 17. | Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 2 months ago | 310950 |
| 18. | Xtrackers S&P 500 Swap ETF 1C | 5 months ago | 308326 |
| 19. | Invesco Technology S&P US Sel Sec ETF | 10 months ago | 303646 |
| 20. | SSgA Russell Small Cap Completeness Idx | 9 months ago | 296886 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 5 months ago | 5653211 |
| 2. | Bvf Inc | 5 months ago | 4629289 |
| 3. | The Goldman Sachs Group Inc | 5 months ago | 4302905 |
| 4. | BlackRock Inc | 8 months ago | 3869130 |
| 5. | Novo A/S | 5 months ago | 3650737 |
| 6. | Vanguard Group Inc | 5 months ago | 3093527 |
| 7. | Armistice Capital, LLC | 5 months ago | 1936000 |
| 8. | HHG PLC | 8 months ago | 1753367 |
| 9. | Federated Hermes Inc | 8 months ago | 1594832 |
| 10. | Point72 Asset Management, L.P. | 5 months ago | 1539860 |
| 11. | Adage Capital Partners Gp LLC | 5 months ago | 1235156 |
| 12. | JPMorgan Chase & Co | 8 months ago | 1027030 |
| 13. | Geode Capital Management, LLC | 5 months ago | 1012025 |
| 14. | State Street Corp | 8 months ago | 903774 |
| 15. | Morgan Stanley - Brokerage Accounts | 8 months ago | 835911 |
| 16. | Bank of America Corp | 8 months ago | 819266 |
| 17. | Deutsche Bank AG | 5 months ago | 704207 |
| 18. | Renaissance Technologies Corp | 5 months ago | 512900 |
| 19. | Parkman Healthcare Partners LLC | 5 months ago | 503431 |
| 20. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 5 months ago | 485389 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...